SCHEMBL8249148

SCHEMBL8249148

O=c1[nH]c2ccccc2n1CCCc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.68
HTT P42858 2/20 0.68
ALDH1A1 P00352 1/20 0.68
MAPT P10636 1/20 0.68
HPGD P15428 1/20 0.68
TSHR P16473 1/20 0.68
MAPK1 P28482 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
TDP1 Q9NUW8 1/20 0.68
POLB P06746 1/20 0.67
HTR7 P34969 5/20 0.59
MEN1 O00255 2/20 0.58
CYP1A2 P05177 2/20 0.58
KMT2A Q03164 2/20 0.58
RAB9A P51151 1/20 0.58
P2RX7 Q99572 4/20 0.55
MLNR O43193 1/20 0.55
NR1I2 O75469 1/20 0.55
CHRM2 P08172 1/20 0.55
CYP3A4 P08684 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24709107 0.95 LMNA (0.66) LMNAHTTALDH1A1MAPTHPGD
SCHEMBL8248960 0.92 LMNA (0.64) LMNAHTTALDH1A1MAPTHPGD
SCHEMBL30947438 0.88 LMNA (0.78) LMNAHTTALDH1A1MAPTHPGD
SCHEMBL8250029 0.83 POLB (0.48) LMNAHTTALDH1A1MAPTHPGD
SCHEMBL891454 0.82 LMNA (0.69) LMNAHTTALDH1A1MAPTHPGD
SCHEMBL6902600 0.82 RAB9A (0.72) LMNAHTTALDH1A1MAPTHPGD
SCHEMBL318943 0.82 LMNA (0.69) LMNAHTTALDH1A1MAPTHPGD
SCHEMBL6397082 0.82 LMNA (0.69) LMNAHTTALDH1A1MAPTHPGD
SCHEMBL30277537 0.82 LMNA (0.69) LMNAHTTALDH1A1MAPTHPGD
SCHEMBL28297946 0.82 LMNA (0.69) LMNAHTTALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896473-B1 1-[[2-AMINO-3-(SUBSTITUTED ALKYL)-3H-BENZIMIDAZOLYL]METHYL]-3-SUBTITUTED-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARM LTD (IE) 2011-10-19 EP disclosed
US-8034835-B2 1-[[2-amino-3-(substituted alkyl)-3H-benzimidazolyl[methyl]-3-substituted-1,3-dihydro-benzoimidazol-2-ones and structural analogs TIBOTEC PHARMACEUTICALS LTD. (IE) 2011-10-11 US disclosed
US-8034835-B2 1-[[2-amino-3-(substituted alkyl)-3H-benzimidazolyl[methyl]-3-substituted-1,3-dihydro-benzoimidazol-2-ones and structural analogs TIBOTEC PHARMACEUTICALS LTD. (IE) 2011-10-11 US disclosed
US-20100183552-A1 1-[2-AMINO-3-(SUBSTITUTED ALKYL)-3H-BENZIMIDAZOLYLMETHYL]-3-SUBSTITUTED-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AND STRUCTURAL ANALOGS JANSSEN SCIENCES IRELAND UC (IE) 2010-07-22 US disclosed
US-20100183552-A1 1-[2-AMINO-3-(SUBSTITUTED ALKYL)-3H-BENZIMIDAZOLYLMETHYL]-3-SUBSTITUTED-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AND STRUCTURAL ANALOGS JANSSEN SCIENCES IRELAND UC (IE) 2010-07-22 US disclosed
WO-2006136561-A1 1- ( 2-AMINO-3- (SUBSTITUTED ALKYL)-3H-BENZIMIDAZOIYLMETHYL) -3-SUBTITUTED-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES WITH ACTIVITY ON RESPIRATORY SYNCYTIAL VIRUS TIBOTEC PHARMACEUTICALS LTD (IE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100183552-A1 1-[2-AMINO-3-(SUBSTITUTED ALKYL)-3H-BENZIMIDAZOLYLMETHYL]-3-SUBSTITUTED-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AND STRUCTURAL ANALOGS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ALK, HRH4 LMNA 830/4885HTT 1612/4885ALDH1A1 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.